Noticias y vídeos - CARDIOME PHARMA - Página 2

Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire VANCOUVER, Nov. 20, 2017 NASDAQ: CRME TSX: COM VANCOUVER , Nov. 20, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that Mr. Justin Renz , Chief Financial Officer of Cardiome, will present at the 29th Annual Piper Jaffray Healthcare Conference. The presentation...

Cardiome Reports Third Quarter 2017 Financial Results PR Newswire VANCOUVER, Nov. 14, 2017 NASDAQ: CRME TSX: COM Management to Host Conference Call and Webcast Today, November 14, 2017 at 4:30 p.m. ET ( 1:30 p.m. PT ) VANCOUVER , Nov. 14, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today reported financial results for the third quarter ended September 30,...

NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Cardiome Pharma Corp. (NASDAQ: CRME ) will be discussing their earnings results in their Q3 Earnings Call to be held on Tuesday, November 14, 2017 at 4:30 PM Eastern Time. To listen to the event live or access a replay of the call - visit: https://www.investornetwork.com/company/23824 To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About...

Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14 PR Newswire VANCOUVER, Nov. 7, 2017 NASDAQ: CRME TSX: COM VANCOUVER , Nov. 7, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that it will report financial results for the third quarter ended September 30, 2017 on Tuesday, November 14, 2017 . Cardiome will hold a...

Cardiome Announces Expansion of Global Geographic Footprint for Brinavess® PR Newswire VANCOUVER, Nov. 2, 2017 – Brinavess ® Launched This Week in South Africa ; New Distribution Agreement Signed for Pakistan – NASDAQ: CRME TSX: COM VANCOUVER , Nov. 2, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the expansion of its geographic presence for Brinavess (vernakalant hydrochloride, IV) into the two new key territories of South Africa and Pakistan....

Cardiome Announces Commercial Launch of Xydalba™ in Three New European Geographies PR Newswire VANCOUVER, Oct. 30, 2017 Marketing and Promotion of Xydalba Has Now Commenced in Six European Countries NASDAQ:CRME TSX:COM VANCOUVER , Oct. 30, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM) today announced that it has initiated the commercial launch of Xydalba™ (dalbavancin hydrochloride) in Sweden , Finland and the Republic of Ireland . Xydalba is approved by the European...

Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel PR Newswire VANCOUVER, Sept. 12, 2017 VANCOUVER , Sept. 12, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has entered into a distribution and license agreement with Basilea for its antibiotic Zevtera ® /Mabelio ® . Under the terms of the agreement, Basilea has granted Cardiome an exclusive license to commercialize ceftobiprole in 34...

Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference PR Newswire VANCOUVER, Sept. 5, 2017 NASDAQ: CRME TSX: COM VANCOUVER , Sept. 5, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Dr. Bill Hunter , President and CEO of Cardiome, will provide an update on the company's progress at the Rodman & Renshaw 19th Annual Global Investment Conference. The presentation will take place at the Lotte New York Palace on Monday September...

New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS® PR Newswire VANCOUVER, Aug. 30, 2017 Results Support the Clinical Utility of BRINAVESS as a Treatment Alternative to Electrical Cardioversion in Patients with Recent Onset Atrial Fibrillation Retrospective Analysis Suggests that Treatment with BRINAVESS Results in Lower Long-Term Relapse Rate at One-Year Relative to Electrical Cardioversion NASDAQ: CRME TSX: COM VANCOUVER , Aug. 30, 2017...

Cardiome Provides U.S. Regulatory Update For BRINAVESS PR Newswire VANCOUVER, Aug. 21, 2017 NASDAQ:CRME TSX:COM VANCOUVER , Aug. 21, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME/ TSX:COM) today announced that it has received a response from the U.S. Food and Drug Administration (FDA) regarding the regulatory path for BRINAVESS ® (vernakalant hydrochloride, IV), the Company's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF). In its written reply,...

Cardiome Reports Second Quarter 2017 Financial Results PR Newswire VANCOUVER, Aug. 8, 2017 NASDAQ: CRME TSX: COM Management to Host Conference Call and Webcast Today, August 8, 2017 at 4:30 p.m. ET ( 1:30 p.m. PT ) VANCOUVER , Aug. 8, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for the second quarter ended June 30, 2017 and commented on recent accomplishments and plans. "Our second quarter was marked by several business development and...

NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Cardiome Pharma Corp. (NASDAQ: CRME ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 4:30 PM Eastern Time. To listen to the event live - visit https://www.investornetwork.com/company/23824 . Replay Information The replay will be available online at https://www.investornetwork.com/company/23824 . About Investor Network Investor Network (IN) is a new financial content community, serving...

Cardiome To Hold Second Quarter 2017 Financial Results Conference Call On August 8 PR Newswire VANCOUVER, Aug. 1, 2017 NASDAQ: CRME TSX: COM VANCOUVER , Aug. 1, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the second quarter ended June 30, 2017 on Tuesday, August 8, 2017 . Cardiome will hold a conference call and webcast at 4:30 p.m. Eastern ( 1:30 p.m. Pacific) on that day to discuss the results. To access the...

Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen PR Newswire VANCOUVER, July 17, 2017 NASDAQ: CRME TSX: COM VANCOUVER , July 17, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM) today announced that the Therapeutic Products Directorate (TPD) of Health Canada has approved the AGGRASTAT ® (tirofiban hydrochloride) 25 mcg/kg (high) dose bolus ("HDB") regimen, as requested under the Company's supplemental New Drug Submission (sNDS). The 25 mcg/kg...

Cardiome's Partner SteadyMed Submits U.S. New Drug Application for TREVYENT® for the Treatment of Pulmonary Arterial Hypertension PR Newswire VANCOUVER, July 3, 2017 NASDAQ:CRME TSX:COM VANCOUVER , July 3, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM) today announced that partner SteadyMed Ltd (NASDAQ:STDY) submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TREVYENT ® (treprostinil injection). TREVYENT ® is a drug-device combination...

Cardiome Pharma Corp. Announces Voting Results PR Newswire VANCOUVER, June 23, 2017 NASDAQ:CRME TSX:COM VANCOUVER , June 23, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the results of voting at its 2017 Annual General and Special Meeting of Shareholders held on June 20, 2017 . A total of 24,583,372 common shares were voted in connection with the meeting, representing approximately 77.00% of the issued and outstanding common shares of the company....

Cardiome Announces Licensing Agreement for XYDALBA™ (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel PR Newswire VANCOUVER, June 21, 2017 NASDAQ:CRME TSX:COM VANCOUVER , June 21, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM) today announced that its affiliate has signed an exclusive license and distribution agreement with Tzamal Medical Ltd. ("Tzamal") that will advance XYDALBA™ toward commercialization in Israel . As part of the agreement,...

Cardiome Announces Commercial Launch of BRINAVESS® (Vernakalant Hydrochloride) in Canada PR Newswire VANCOUVER, June 12, 2017 NASDAQ:CRME TSX:COM VANCOUVER , June 12, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM) today announced that it received authorization from Health Canada to begin selling BRINAVESS ® (vernakalant hydrochloride, IV) and has subsequently launched BRINAVESS ® in Canada . BRINAVESS ® is indicated for the rapid conversion of recent onset atrial...

Cardiome Reports Changes To Senior Management Team PR Newswire VANCOUVER, May 16, 2017 NASDAQ: CRME TSX: COM VANCOUVER , May 16, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced a number of changes to its senior management team. Commenting on the changes, William Hunter , MD, CEO and President of Cardiome, said "Cardiome is a very different company than it was even a few years ago. We are no longer focused on a single drug and are now a diversified Company...

Cardiome Reports First Quarter 2017 Financial Results PR Newswire VANCOUVER, May 15, 2017 NASDAQ: CRME TSX: COM Cardiome to conduct conference call and webcast today, May 15, 2017 at 4:30 p.m. Eastern ( 1:30 p.m. Pacific) VANCOUVER , May 15, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for its first quarter ended March 31, 2017 . Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted...